Table 1 Baseline clinical characteristics for all patients

Age (years)

57 (28–79)

50 (23–78) ^¥

49 (30–72) ^ф

56 (28–79)

55 (23–75)

Women, n (%)

47 (73)

12 (41) ^¥

4 (20) ^ɸ€

30 (61)

33 (52)

Rheumatic disease duration (years)

2 (0–30)

3 (0–37)

3 (0–40)

0.10 (0–25)

3.7 (0–40)*

 CRP (mg/L)

8 (1–78)

5 (1–99)

10 (1–157)

8 (1–99)

6.5 (1–157)

 ESR (mm/h)

18.5 (1–81)

7 (2–48) ^¥

9.5 (2–87) ^ɸ

14 (1–81)

13 (2–87)

 Anti-CCP, n (%)

39 (61)

–

–

17 (35)

22(34)

 Rheumatoid factor IgA, n (%)

32 (50)

–

–

15 (31)

17 (27)

 Rheumatoid factor IgM, n (%)

45 (70)

–

–

22(45)

23(36)

 BASDAI

–

4.73 (0.3–9.5)

5.1 (0.9–9.6)

5.5 (0.3–9.3)

5.1 (0.9–9.7)

 BASFI

–

3.2(0–9)

4.1 (1.1–7.6)

3.0 (0–9)

3.8 (0.4–8.6)

 BASMI

–

–

3 (0–10)

–

3 (0–10)

 DAS28

4.98 (2.6–7.3)

–

–

5.2 (3.1–7.3)

5.1(2.6–7.1)

 PtGA

52 (5–98)

44 (2–96)

56 (6–96)

52 (2–96)

49 (6–98)

 PGA

38 (7–73)

21 (0–57) ^¥

26 (3–60) ^ф

38 (11–73)

27(0–73)*

 MHAQ

0.65 (0–1.45)

0.40 (0.05–1.55)

0.43 (0–1.40)

0.45 (1–1.55)

0.50 (0–1.40)

 Anti-TNF monotherapy

0 (0)

4 (14) ^¥

20 (100) ^ɸ€

0

24 (38)*

 MTX monotherapy

34 (53)

15 (52)

0 (0) ^ɸ€

49 (100)

0 (0)*

 Anti-TNF ± MTX

30 (47)

10 (34)

0 (0) ^ɸ€

0 (0)

40 (62)*

 Beta-blockers

5 (8)

1 (3)

4 (20)

4 (8)

6 (9)

 Calcium antagonists

5 (8)

2 (7)

2 (10)

2 (4)

7 (11)

 ACE inhibitors

6 (9)

1 (3)

2 (10)

4 (8)

5 (8)

 NSAIDs

47 (73)

14 (48) ^¥

14 (70)

35 (71)

40 (62)

 Coxibs

0 (0)

0 (0)

1 (5)

0 (0)

1 (2)

 Statins

12 (19)

1 (3) ^¥

7 (35) ^€

7 (14)

13 (20)

 Acetyl salicylic acid

6 (9)

2 (7)

3 (15)

6 (12)

5 (8)

 Warfarin

0 (0)

0 (0)

1 (5) ^€

0 (0)

1 (2)

 Glucocorticoids

17 (27)

3 (10) ^¥

2 (10) ^ɸ

8 (16)

15 (23)*